BIO-TECHNE APPOINTS DR. JUDITH KLIMOVSKY TO BOARD OF DIRECTORS

Rhea-AI Summary

• English
• French
• German
• Italian
• Korean
• Spanish

Bio-Techne appointed Dr. Judith Klimovsky as an independent director on the Board of Directors, bringing valuable experience from the biotechnology industry. Dr. Klimovsky's background in antibody therapeutics and global clinical development positions her well to contribute to Bio-Techne's expansion efforts. The addition of Dr. Klimovsky enhances the board's expertise and diversity, with a focus on Latin America and global biopharma.

Positive

• Dr. Judith Klimovsky's appointment adds valuable scientific and international experience to Bio-Techne's board.

• Dr. Klimovsky's background in antibody therapeutics and extensive global biopharma experience will benefit Bio-Techne's development initiatives.

• The temporary expansion of Bio-Techne's board to include Dr. Klimovsky highlights the company's commitment to enhancing its leadership team with diverse expertise.

Negative

• None.

MINNEAPOLIS, April 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the appointment of Dr. Judith Klimovsky to serve as an independent director on the Company's Board of Directors, April 24, 2024. Dr. Klimovsky will serve as a member of the Science and Technology Committee. Following the appointment, the board of Bio-Techne will be temporarily comprised of eleven directors, ten of whom are independent.

Dr. Klimovsky is currently the Executive Vice President and Chief Development Officer at Genmab, an international biotechnology company specialized in the creation and development of antibody therapeutics. Before joining Genmab in 2017, Dr. Klimovsky held various senior global clinical and research positions at Novartis Oncology, a division of Novartis AG, including SVP & Global Head, Oncology Clinical Development. Dr. Klimovsky also served as Regional Medical Director, Latin America for Merck & Co. and held several research and development roles of increasing responsibility at Bristol-Myers Squibb Company. Dr. Klimovsky received her M.D. from the Universidad de Buenos Aires.

Dr. Klimovsky previously (from 2018 to Feb 2024) served as a Director of Bellicum Pharmaceuticals, a company discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors.  

"We are pleased to welcome Dr. Klimovsky to our board," said Bob Baumgartner, Chairman of the Board of Bio-Techne. "She brings tremendous scientific and international experience, including running large development groups at global biopharma companies. She also has extensive experience in Latin America, which will bring important expertise as Bio-Techne continues to expand globally."

About Bio-Techne Corporation (NASDAQ: TECH) 

Contact:
David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com 
612-656-4416

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-appoints-dr-judith-klimovsky-to-board-of-directors-302129811.html

SOURCE Bio-Techne Corporation

FAQ

Who was appointed to Bio-Techne's Board of Directors?

Dr. Judith Klimovsky was appointed as an independent director on Bio-Techne's Board of Directors.

What is Dr. Judith Klimovsky's background?

Dr. Judith Klimovsky has experience in antibody therapeutics, global clinical development, and has held senior positions at biopharma companies like Novartis Oncology and Genmab.

What role will Dr. Judith Klimovsky serve at Bio-Techne?

Dr. Judith Klimovsky will serve as a member of the Science and Technology Committee on Bio-Techne's Board of Directors.

What is the current composition of Bio-Techne's board after the appointment?

Following Dr. Judith Klimovsky's appointment, Bio-Techne's board will have eleven directors, with ten being independent.

What companies did Dr. Judith Klimovsky work for before joining Bio-Techne?

Before joining Bio-Techne, Dr. Judith Klimovsky worked at companies like Genmab, Novartis Oncology, Merck & Co., and Bristol-Myers Squibb Company.